AI Engines For more Details: Perplexity Kagi Labs You
Muscle Spasms: Cyclobenzaprine hydrochloride is indicated for the relief of acute musculoskeletal conditions associated with painful muscle spasms. It works centrally within the nervous system to reduce muscle spasm and tension, leading to muscle relaxation. Conditions that may benefit from cyclobenzaprine hydrochloride treatment include muscle strains, sprains, and other musculoskeletal injuries or conditions causing muscle spasms.
Musculoskeletal Pain: In addition to reducing muscle spasms, cyclobenzaprine hydrochloride may also help alleviate associated musculoskeletal pain. By inducing muscle relaxation, it can contribute to pain relief in individuals experiencing discomfort due to muscle tension or spasm-related pain. However, it is important to note that cyclobenzaprine hydrochloride is not typically prescribed as a standalone analgesic but rather as an adjunctive therapy to address muscle-related pain.
Fibromyalgia: Cyclobenzaprine hydrochloride may be used off-label in the treatment of fibromyalgia, a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, and tenderness at specific points on the body. While not approved specifically for fibromyalgia, cyclobenzaprine hydrochloride's muscle relaxant properties may help alleviate muscle stiffness and tension, thereby reducing pain and improving overall symptoms in some individuals with fibromyalgia.
Dosage and Administration: Cyclobenzaprine hydrochloride is typically administered orally in the form of tablets or extended-release capsules. The dosage and duration of treatment depend on factors such as the severity of muscle spasm or pain, the individual patient's response to therapy, and any underlying medical conditions. It is usually taken two to three times daily, with or without food. Cyclobenzaprine hydrochloride is intended for short-term use, typically not exceeding two to three weeks, due to the risk of tolerance, dependence, and potential adverse effects associated with prolonged use.
Side Effects: Common side effects of cyclobenzaprine hydrochloride may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and confusion, particularly in elderly individuals. It may also cause anticholinergic effects such as urinary retention, tachycardia (rapid heart rate), and cognitive impairment. Rare but serious side effects may include serotonin syndrome (when used concomitantly with serotonergic medications), cardiac arrhythmias, and allergic reactions. Patients should be monitored for side effects during cyclobenzaprine hydrochloride therapy, and treatment should be adjusted or discontinued if adverse reactions occur.
Contraindications and Precautions: Cyclobenzaprine hydrochloride should be used with caution in patients with certain medical conditions, including glaucoma, urinary retention, cardiovascular disease, hepatic impairment, and hyperthyroidism. It is contraindicated in individuals with a history of cardiac arrhythmias, recent myocardial infarction (heart attack), or hypersensitivity to cyclobenzaprine hydrochloride or related compounds. Cyclobenzaprine hydrochloride may also interact with other medications, particularly central nervous system depressants, serotonergic drugs, and monoamine oxidase inhibitors (MAOIs), increasing the risk of adverse effects or drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.8 | 0 |
| Allergies | 7.4 | 4.5 | 0.64 |
| Allergy to milk products | 2.4 | 1.6 | 0.5 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 6.5 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.4 | 2.07 |
| Ankylosing spondylitis | 5.2 | 1.2 | 3.33 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
| Asthma | 5.9 | 3.4 | 0.74 |
| Atherosclerosis | 2.5 | 2.4 | 0.04 |
| Atrial fibrillation | 4.1 | 2.8 | 0.46 |
| Autism | 10.8 | 11.4 | -0.06 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 0.9 | 2.8 | -2.11 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 2.8 | 4 | -0.43 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 5.3 | 6.7 | -0.26 |
| Chronic Kidney Disease | 4.5 | 3.1 | 0.45 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 2 | -0.11 |
| Chronic Urticaria (Hives) | 1.8 | 1.8 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.2 | 2.6 | 2.15 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.2 | 3 | -0.36 |
| COVID-19 | 11.7 | 12.8 | -0.09 |
| Crohn's Disease | 8.8 | 6.9 | 0.28 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 1.9 | -0.9 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 3.5 | 1.4 | 1.5 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 12.1 | 9.5 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.1 | -0.24 |
| Endometriosis | 3.3 | 2.5 | 0.32 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.3 | 2.9 | 0.48 |
| erectile dysfunction | 1.6 | 0.3 | 4.33 |
| Fibromyalgia | 3.4 | 2.1 | 0.62 |
| Functional constipation / chronic idiopathic constipation | 6.1 | 4.9 | 0.24 |
| gallstone disease (gsd) | 3.6 | 1.6 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 1.2 | 0.58 |
| Generalized anxiety disorder | 3.1 | 3 | 0.03 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.2 | 1.3 | 0.69 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 4.4 | 2 | 1.2 |
| Heart Failure | 4.1 | 2.4 | 0.71 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.8 | 0.6 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2.4 | 2.2 | 0.09 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 5.8 | 6 | -0.03 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.9 | 0.9 | 3.33 |
| IgA nephropathy (IgAN) | 1.9 | 4.9 | -1.58 |
| Inflammatory Bowel Disease | 9 | 10.7 | -0.19 |
| Insomnia | 2 | 3.5 | -0.75 |
| Intelligence | 1.8 | 0.6 | 2 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.7 | 6.4 | 0.36 |
| ischemic stroke | 3.6 | 1.7 | 1.12 |
| Liver Cirrhosis | 7.7 | 5.5 | 0.4 |
| Long COVID | 6.9 | 8.9 | -0.29 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.6 | -0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.7 | 1.9 | -1.71 |
| ME/CFS without IBS | 1.4 | 2.4 | -0.71 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 7.8 | 8.7 | -0.12 |
| Mood Disorders | 12.2 | 8.5 | 0.44 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 7.7 | 7 | 0.1 |
| Multiple system atrophy (MSA) | 1.3 | 0.7 | 0.86 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6 | 5.9 | 0.02 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.3 | 8.4 | 0.35 |
| obsessive-compulsive disorder | 6.8 | 4.2 | 0.62 |
| Osteoarthritis | 2.4 | 1.7 | 0.41 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 9.6 | 7.2 | 0.33 |
| Polycystic ovary syndrome | 7.2 | 3.4 | 1.12 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.5 | 2.6 | -0.04 |
| Psoriasis | 4.3 | 4 | 0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.1 | 4.7 | 0.72 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.5 | 3.6 | 1.08 |
| scoliosis | 0.7 | 0.9 | -0.29 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.3 | 0.3 | 3.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 0.6 | 2.5 |
| Stress / posttraumatic stress disorder | 3.6 | 3.3 | 0.09 |
| Systemic Lupus Erythematosus | 4 | 2.3 | 0.74 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.8 | 4.4 | 0.09 |
| Type 2 Diabetes | 9 | 9.4 | -0.04 |
| Ulcerative colitis | 6 | 8 | -0.33 |
| Unhealthy Ageing | 5 | 2.9 | 0.72 |
| Vitiligo | 2.5 | 1.6 | 0.56 |
